MTW NHS Trust West Kent CCG

Drug Status Key

  • Preferred
  • Second Line
  • Third Line
  • Specialist Initiation
  • Hospital Only
  • Not Approved for Formulary

Calcium regulating drugs

National Guidance

 NICE Osteoporosis pathway, February 2018

 National Osteoporosis Guideline Group (NOGG) Clinical guideline for the prevention and treatment of osteoporosis, updated July 2018

 TA161 Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in post menopausal women, updated February 2018

Calcitonin is a hormone produced by the thyroid gland and is involved in helping to regulate levels of calcium and phosphate in the blood, opposing the action of parathyroid hormone and slows bone turnover. Calcitonin is licensed for prevention of bone loss due to sudden immobility, hypercalcaemia of malignancy and for the treatment of Paget's disease. It is not recommended for osteoporosis treatment because benefit is outweighed by the risk of malignancy associated with long-term use.

Teriparatide is a recombinant protein form of parathyroid hormone. It is licensed for the treatment of osteoporosis in post menopausal women and in men at increased risk of fractures. Use can only be initiated by a specialist consultant according to NICE guidance.